{
  "_id": "0dadbaaecf06e8e363219b30edbd0d82e3b29296c820c6e63204c431fd937cb7",
  "feed": "wall-street-journal",
  "title": "Merck Eyes Purchase of Biotech Seagen; Pulling off a deal could be tricky given the risk of a regulatory challenge, and it is possible the companies could end up striking a marketing agreement instead",
  "text": "<p>Other unnamed suitors are also eying Seagen, a perennially speculated takeover target, some of the people said.</p><p>If there is a deal, it would be significant, given Seagen's market value of roughly $28 billion.</p><p>(More to come)</p><p>Jonathan D. Rockoff contributed to this article.</p><p>Write to Cara Lombardo at cara.lombardo@wsj.com, Miriam Gottfried at Miriam.Gottfried@wsj.com and Dana Cimilluca at dana.cimilluca@wsj.com</p><p>Merck Eyes Purchase of Biotech Seagen</p>",
  "published": "2022-06-17T14:30:00.000Z",
  "tags": [
    {
      "id": "US58933Y1055",
      "nexusId": "10042334",
      "name": "Merck & Co., Inc.",
      "offsets": [
        {
          "start": 0,
          "end": 5
        },
        {
          "start": 412,
          "end": 417
        }
      ]
    }
  ]
}